Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Free Cash Flow (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Free Cash Flow for 12 consecutive years, with -$587582.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 16.31% year-over-year to -$587582.0, compared with a TTM value of -$3.0 million through Dec 2025, down 65.07%, and an annual FY2025 reading of -$3.0 million, down 65.07% over the prior year.
  • Free Cash Flow was -$587582.0 for Q4 2025 at Abvc Biopharma, up from -$964710.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $60230.0 in Q3 2024 and bottomed at -$3.5 million in Q2 2022.
  • Average Free Cash Flow over 5 years is -$1.2 million, with a median of -$919689.0 recorded in 2023.
  • The sharpest move saw Free Cash Flow surged 106.41% in 2024, then crashed 1701.71% in 2025.
  • Year by year, Free Cash Flow stood at -$2.5 million in 2021, then surged by 81.73% to -$461158.0 in 2022, then increased by 6.66% to -$430463.0 in 2023, then tumbled by 63.11% to -$702134.0 in 2024, then rose by 16.31% to -$587582.0 in 2025.
  • Business Quant data shows Free Cash Flow for ABVC at -$587582.0 in Q4 2025, -$964710.0 in Q3 2025, and -$894174.0 in Q2 2025.